A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase III
Latest Information Update: 23 Jan 2020
Price : $35 *
At a glance
- Drugs Upadacitinib (Primary) ; Dupilumab
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms Heads UP
- Sponsors AbbVie
- 03 Jan 2020 Planned End Date changed from 8 Sep 2020 to 22 Jan 2021.
- 03 Jan 2020 Planned primary completion date changed from 8 Sep 2020 to 22 Jan 2021.
- 15 Nov 2019 New source identified and integrated: European Clinical Trials Database (EudraCT2019-001227-12).